Big week in the world of psychedelics. Had a few policy changes and big updates with the FDA accepting an Investigational New Drug for treating PTSD.
We're getting closer and closer to finally being able to get the use cases psychedelics were meant for, with new studies showing some serious potential for a future without mental health disorders.
The Legal Mumbo Jumbo
On January 13, 2026, New Jersey legislature passed a bill to start establishing psilocybin pilot programs. This $6 million dollar bill aims to focus on providing safe access to psilocybin therapy. Aiming to target depression and substance abuse.
New York is also on the ball getting a similar bill amended and recommitted. This bill is focused more on treating veterans and first responders. Huge news all around for both states. It's nice to see psilocybin finally being used to heal and reset the mind.
On January 16, 2026, Texas partners were announced for the Texas Ibogaine Research Consortium. The state is aiming to claim the title of excellence for psychedelic medicine. The focus is gathering clinical data to support FDA approval of ibogaine, which is a psychoactive substance found in the Tabernanthe iboga shrub. Another study targeting addiction and PTSD.
On the smaller side of things Arizona opened up its application process for psychedelic assisted therapy centers. Good to see them taking the first steps to implement psilocybin research!
For some reason we saw the DEA increase quotas. We saw a significant raise in the legal limits for the following:
Psilocybin = Raised to 50k grams. Up 30k since 2024
Psilocyn= raised to 80k grams. 2x the previous limits
5-MeO-DMT= Raised 30k grams. Up 19k since 2025
You're probably wondering what this means. But it's really simple, the government must be anticipating a surge in larger scaled clinical trials. Or maybe even the demand for a possible commercial use. Odds are they ain't making more for nothing.
The Fungi Science
Dartmouth published a banger study this week on January 13.
The study found that by targeting a certain receptor they could give the same healing benefits, without the user having to experience the trip.
Here's how it works ⬇️
This is a pretty big discovery that could allow the development of new drugs that offer the same benefits as our beloved magic mushroom, without the trip 🤯
Meaning instead of sitting through a 6-8 hour guided session, you could just chill at home. Be less depressed, stressed and anxious!
FDA Greenlights Compass
It was confirmed earlier this week that the FDA confirmed Compass Pathways synthetic psilocybin called COMP360. This allowed the team to continue with their trials specifically targeting PTSD.
This will be the stage 2b/3 clinical trials. If they can succeed and calming the chaos of PTSD it will be a huge breakthrough that can put the minds at many people at ease.
Another Week
Crazy week for psychedelics. We're so close to the brink of a new healing era and it's all inspired by a shroom. Something that holds a mystic power we still can't explain. As the tech gets better and restrictions and policies continue to change, it won't be long before the magic of the mushroom is making the world a better place 🍄
Hope you enjoyed this weeks Fungi news!!
Looking forward to continuing this and improving the style flow going forward!!
See ya next week!